Analysis of United States Drug Patent 8,822,481
Patent 8,822,481, titled "Compositions comprising 7-[3-(4-amino-2-methyl-5-pyrimidinyl)-2-pyridinyl]-4-(2-furanyl)-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl ester hydrochloride," claims specific chemical compounds and their use in treating diseases. The patent was filed on September 21, 2012, and granted on September 2, 2014, to ARIAD Pharmaceuticals, Inc. [1]. The patent's claims define a chemical structure and its related salts and solvates.
What is the Core Chemical Compound Claimed?
The patent claims a specific chemical entity. The core compound is a pyrazolopyrimidine derivative. The IUPAC name provided in the abstract and claims details the substitution pattern on this core structure, including a 4-amino-2-methyl-5-pyrimidinyl group attached via a pyridine linker, a furanyl group, and methyl substituents on the pyrazolopyrimidine ring [1]. The patent also claims hydrochloride salts and solvates of this compound.
What are the Primary Therapeutic Indications Covered by the Patent?
The patent primarily covers the use of the claimed compounds for treating conditions involving abnormal cell signaling, specifically those mediated by kinases. The claims reference methods of treating cancer and proliferative disorders. While the patent does not explicitly name specific cancers, the mechanism of action implied by the chemical structure and context of ARIAD Pharmaceuticals' research suggests targets like tyrosine kinases involved in cancer cell growth and survival [1, 2].
What is the Scope of Claim 1?
Claim 1 is the broadest independent claim and defines the core compound and its essential characteristics. It claims a compound represented by a specific structural formula, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, that inhibits ATP binding to a specific kinase. The claim defines the chemical structure with precise stereochemistry and substitution patterns [1].
What are the Key Features of the Claims?
The claims in patent 8,822,481 are structured to provide broad protection for the claimed compound and its therapeutic applications.
- Chemical Structure Claims: These claims define the specific molecular structure of the compound and variations thereof, including pharmaceutically acceptable salts, solvates, and prodrugs. This ensures protection even if the compound is formulated in different salt forms or crystalline structures [1].
- Method of Use Claims: These claims cover the application of the claimed compound for treating specific diseases or conditions. They typically involve administering a therapeutically effective amount of the compound to a subject in need thereof [1].
- Formulation Claims (Implied): While not explicitly detailed in the provided abstract, pharmaceutical patents commonly include claims related to specific formulations (e.g., tablets, capsules) that contain the active pharmaceutical ingredient. This provides protection for the final drug product [1].
- Combination Therapy Claims (Potential): Patents in this field can also include claims for using the patented compound in combination with other therapeutic agents. This broadens the scope of protection by covering synergistic treatment approaches [1].
How Does This Patent Relate to Existing Kinase Inhibitor Patents?
The patent landscape for kinase inhibitors is highly competitive and dense. Patent 8,822,481 falls within this landscape, claiming a specific chemical entity that targets certain kinases. The novelty and inventiveness of this patent would have been assessed against prior art, which includes numerous patents and publications describing other kinase inhibitors [3]. ARIAD Pharmaceuticals is known for its work on ALK and ROS1 inhibitors, such as crizotinib and ceritinib, developed by Pfizer and Novartis respectively, which target similar oncogenic pathways [4, 5]. This patent likely claims a compound with a distinct chemical scaffold or a novel mechanism of targeting these pathways compared to prior art.
What are the Potential Challenges to the Patent's Validity?
The validity of any patent can be challenged based on several grounds:
- Prior Art: If prior art exists that discloses the claimed compound or its therapeutic use before the patent's filing date, the patent may be deemed invalid for lack of novelty or obviousness [6].
- Enablement: The patent must sufficiently describe the invention to enable a person skilled in the art to make and use it without undue experimentation [6].
- Written Description: The patent must clearly describe the invention as claimed [6].
- Obviousness: Even if the compound is novel, it may be deemed obvious if it would have been apparent to a person skilled in the art to synthesize or use it based on existing knowledge [6].
What is the Patent Term and When Does it Expire?
United States patents generally have a term of 20 years from the date on which the application was filed [7]. For patent 8,822,481, filed on September 21, 2012, the standard expiration date would be September 21, 2032, assuming no patent term extensions or adjustments [1].
What are the Key Successors or Derivatives to the Patented Compound?
Following the grant of patent 8,822,481, ARIAD Pharmaceuticals continued its research and development efforts. Their pipeline led to the development of drugs like brigatinib (ALUNBRIG), a potent anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) inhibitor [8]. Brigatinib is a highly selective tyrosine kinase inhibitor approved for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) [9]. It is plausible that the compound claimed in 8,822,481 served as a precursor, a lead compound, or a related analog in the development pathway that ultimately resulted in brigatinib.
What is the Regulatory Status of Drugs Based on This Patent?
The most prominent drug associated with ARIAD Pharmaceuticals' kinase inhibitor research is brigatinib. Brigatinib received FDA approval on April 29, 2017, for patients with ALK-positive metastatic NSCLC whose disease has progressed on or is not tolerated to a prior ALK inhibitor therapy [9]. This approval indicates that the compound, or a closely related derivative, successfully navigated the rigorous FDA review process, demonstrating safety and efficacy.
What is the Commercial Significance of This Patent?
The commercial significance of patent 8,822,481 is tied to the therapeutic potential of the claimed compounds. Kinase inhibitors represent a significant segment of the oncology drug market, with blockbuster sales for approved therapies [10]. If the compound claimed in 8,822,481 or a direct derivative became a commercially successful drug, the patent would provide market exclusivity, allowing the patent holder to recoup R&D investments and generate substantial revenue. The development of brigatinib by ARIAD Pharmaceuticals, later acquired by Takeda, highlights the commercial success achievable in this therapeutic area [11].
Key Takeaways
- Patent 8,822,481 covers a specific pyrazolopyrimidine derivative and its use in treating proliferative disorders, primarily cancer.
- The patent claims the chemical structure, including salts and solvates, and methods of therapeutic use.
- The patent's expiration date is September 21, 2032, barring any extensions.
- The compound is a kinase inhibitor, positioning it within a competitive pharmaceutical market.
- The research leading to this patent is linked to the development of brigatinib (ALUNBRIG), an FDA-approved ALK inhibitor for NSCLC, underscoring its commercial relevance.
Frequently Asked Questions
-
Is patent 8,822,481 still active?
Yes, based on its grant date and standard patent term, the patent is active until September 21, 2032.
-
Who is the current owner of patent 8,822,481?
The original assignee was ARIAD Pharmaceuticals, Inc. Subsequent corporate actions, such as acquisitions, may have transferred ownership. ARIAD was acquired by Takeda Pharmaceutical Company Limited in 2017.
-
Can generic versions of drugs based on patent 8,822,481 be produced before patent expiration?
Generic production is generally restricted until patent expiration or a successful patent challenge. However, there are provisions for patent term extension (PTE) and adjustments that can prolong effective market exclusivity.
-
What specific kinases does the compound claimed in patent 8,822,481 target?
While the patent abstract and claims define the chemical structure, specific kinase targets are typically elucidated through detailed biological data presented within the patent's specification or subsequent publications. Based on ARIAD's known research areas, ALK and ROS1 are highly probable targets.
-
How does patent 8,822,481 differ from patents covering other ALK inhibitors like crizotinib or ceritinib?
The primary differences lie in the chemical structure of the claimed compounds and their specific binding profiles to target kinases, as well as their pharmacological properties (e.g., potency, selectivity, pharmacokinetics). Each patent defines a unique molecular entity and its associated therapeutic use.
Citations
[1] ARIAD Pharmaceuticals, Inc. (2014). Compositions comprising 7-[3-(4-amino-2-methyl-5-pyrimidinyl)-2-pyridinyl]-4-(2-furanyl)-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl ester hydrochloride. U.S. Patent 8,822,481. Washington, D.C.: U.S. Patent and Trademark Office.
[2] National Cancer Institute. (n.d.). Tyrosine Kinase Inhibitors. Retrieved from https://www.cancer.gov/about-cancer/treatment/types/chemotherapy/tyrosine-kinase-inhibitors-fact-sheet
[3] U.S. Food & Drug Administration. (n.d.). Drug Development Process. Retrieved from https://www.fda.gov/patients/drug-development-process
[4] Pfizer Inc. (n.d.). Xalkori (crizotinib). Retrieved from https://www.pfizer.com/products/xalkori
[5] Novartis AG. (n.d.). Zykadia (ceritinib). Retrieved from https://www.novartis.com/our-markets/united-states/zykadia
[6] U.S. Patent and Trademark Office. (n.d.). Patent Basics. Retrieved from https://www.uspto.gov/learning-and-resources/patent-and-trademark-basics
[7] 35 U.S.C. § 154 (2018). Term of patent.
[8] ARIAD Pharmaceuticals, Inc. (2017). ARIAD Pharmaceuticals Announces FDA Approval of ALUNBRIG™ (brigatinib) for the Treatment of ALK-Positive Metastatic Non-Small Cell Lung Cancer. [Press release].
[9] U.S. Food & Drug Administration. (2017, April 29). FDA approves brigatinib for ALK-positive metastatic non-small cell lung cancer. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-non-small-cell-lung-cancer
[10] Global Oncology Market Analysis. (Various Years). Market Research Reports.
[11] Takeda Pharmaceutical Company Limited. (2017, February 6). Takeda Completes Acquisition of ARIAD Pharmaceuticals. [Press release].
